Annexin Pharmaceuticals AB (FRA:Q910) PB Ratio: 6.20 (As of Jul. 05, 2026)


FRA:Q910 Annexin Pharmaceuticals AB FRA:Q910
13 GF Score
Price €1.16
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB PB Ratio?

Annexin Pharmaceuticals AB FRA:Q910 +12.62% 13 PB Ratio is 6.20 as of Jul. 05, 2026. GuruFocus rates FRA:Q910 with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,230 Biotechnology companies, Annexin Pharmaceuticals AB ranks worse than 76.26% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Annexin Pharmaceuticals AB's share price is €1.16. Annexin Pharmaceuticals AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.19. Hence, Annexin Pharmaceuticals AB's PB Ratio of today is 6.20.

The historical rank and industry rank for Annexin Pharmaceuticals AB's PB Ratio or its related term are showing as below:

FRA:Q910' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 6.46
Current: 6.46

During the past 11 years, Annexin Pharmaceuticals AB's highest PB Ratio was 6.46. The lowest was 0.00. And the median was 0.00.

FRA:Q910's PB Ratio is ranked worse than
76.26% of 1230 companies
in the Biotechnology industry
Industry Median: 2.98 vs FRA:Q910: 6.46

During the past 12 months, Annexin Pharmaceuticals AB's average Book Value Per Share Growth Rate was 40.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -32.70% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Annexin Pharmaceuticals AB was -20.10% per year. The lowest was -52.60% per year. And the median was -36.40% per year.

Back to Basics: PB Ratio


Annexin Pharmaceuticals AB  (FRA:Q910) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Annexin Pharmaceuticals AB PB Ratio Related Terms


Annexin Pharmaceuticals AB PB Ratio Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB PB Ratio Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 3.16 11.75 5.46

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.10 5.35 5.46 6.12

FRA:Q910 vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexin Pharmaceuticals AB PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's PB Ratio falls into.


FRA:Q910
13GF Score
Annexin Pharmaceuticals AB FRA:Q910
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Annexin Pharmaceuticals AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=1.16/0.187
=6.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 6.20 mean?
Annexin Pharmaceuticals AB (FRA:Q910) has a PB Ratio of 6.20 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annexin Pharmaceuticals AB and its competitors. According to the industry distribution chart, Annexin Pharmaceuticals AB ranks #938 out of 1230 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Annexin Pharmaceuticals AB's PB Ratio too high?
Annexin Pharmaceuticals AB's current PB Ratio is 6.20. The Biotechnology industry median PB Ratio is 2.98. Annexin Pharmaceuticals AB's value of 6.20 is 108.1% above this industry median. Based on the distribution chart, Annexin Pharmaceuticals AB ranks #938 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Annexin Pharmaceuticals AB ranks #938 out of 1230 companies for PB Ratio. This places Annexin Pharmaceuticals AB in the lower half of its industry. The industry median PB Ratio is 2.98. Annexin Pharmaceuticals AB's value of 6.20 is 108.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.98, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annexin Pharmaceuticals AB's current PB Ratio of 6.20 is 108.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annexin Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexin Pharmaceuticals AB's current PB Ratio is 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (FRA:Q910) has a current PB Ratio of 6.20. The current PB Ratio is 6.20 and 108.1% above the Biotechnology industry median of 2.98. Annexin Pharmaceuticals AB's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (FRA:Q910), the current PB Ratio is 6.20 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges ANNX:Sweden
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
13GF Score

Get the complete analysis for FRA:Q910

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.16
Price